Finanzen von NervGen Pharma Corp (NGEN)NGENNervGen Pharma Corp

Evaluating the bottom line, NervGen Pharma Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -757.48%, provide a clear picture of how effectively NGEN converts its operational activities into shareholder value.

In the context of the broader market, NGEN competes directly with industry leaders such as TARA and DERM. With a market capitalization of $142.06M, it holds a leading position in the sector. When comparing efficiency, NGEN's gross margin of N/A stands against TARA's N/A and DERM's 61.58%. Such benchmarking helps identify whether NervGen Pharma Corp is trading at a premium or discount relative to its financial performance.

Nervgen Pharma has reported significant losses, with a net income loss of CAD 29,217,233 in Q2 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near term. The gross profit has been negative in multiple quarters, reflecting ongoing financial struggles.